Sarepta Therapeutics Inc
SRPT
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.38B
Close$
$153.22
581% upside
Current Fair Value
581% upsideUndervalued by 581% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.38 Billion |
|---|---|
| Enterprise Value | $2.96 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.13 |
| Beta | 0.21 |
| Outstanding Shares | 105,431,000 |
Return
| Return on Equity | -17.42% |
|---|---|
| Return on Assets | -8.35% |
| Return on Invested Capital | -8.04% |
Valuation & Multiples
| P/E Ratio | -15.63 |
|---|---|
| PEG | 15.25 |
| Price to Sales | 1.25 |
| Price to Book Ratio | 1.61 |
| Enterprise Value to Revenue | 1.5 |
| Enterprise Value to EBIT | -13.71 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.39 |
| Debt to Equity | 0.76 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.22
Average shareholder expectationRevenue Estimate
$366.39 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$0.17
Average shareholder expectationRevenue Estimate
$354.38 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.3306▲ 33.56% |
|---|---|
| Total Calls | 2,327,965▼ 36.79% |
| Total Puts | 3,097,700▼ 15.47% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 105.27%▲ 7.06% |
|---|---|
| Total Invested | $2.06B▼ 7.55% |
| Investors Holding | 347▼ 24.00% |
ESG Score
No data
About Sarepta Therapeutics Inc
CEO: Douglas Ingram Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the...